A detailed history of Jpmorgan Chase & CO transactions in Immuneering Corp stock. As of the latest transaction made, Jpmorgan Chase & CO holds 2,424 shares of IMRX stock, worth $5,090. This represents 0.0% of its overall portfolio holdings.

Number of Shares
2,424
Previous 1,974 22.8%
Holding current value
$5,090
Previous $2,000 200.0%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 08, 2024

BUY
$1.03 - $3.21 $463 - $1,444
450 Added 22.8%
2,424 $6,000
Q2 2024

Aug 12, 2024

SELL
$1.28 - $2.75 $9,363 - $20,116
-7,315 Reduced 78.75%
1,974 $2,000
Q1 2024

May 10, 2024

SELL
$1.91 - $7.32 $12,959 - $49,666
-6,785 Reduced 42.21%
9,289 $26,000
Q4 2023

Feb 12, 2024

SELL
$4.84 - $8.44 $20,739 - $36,165
-4,285 Reduced 21.05%
16,074 $118,000
Q3 2023

Nov 14, 2023

BUY
$7.21 - $10.68 $25,790 - $38,202
3,577 Added 21.31%
20,359 $156,000
Q2 2023

Aug 11, 2023

BUY
$6.49 - $13.36 $102,230 - $210,446
15,752 Added 1529.32%
16,782 $170,000
Q1 2023

May 11, 2023

BUY
$3.78 - $10.38 $264 - $726
70 Added 7.29%
1,030 $10,000
Q4 2022

Feb 13, 2023

SELL
$4.09 - $15.0 $748 - $2,745
-183 Reduced 16.01%
960 $5,000
Q3 2022

Nov 14, 2022

BUY
$5.0 - $14.32 $50 - $143
10 Added 0.88%
1,143 $16,000
Q2 2022

Aug 11, 2022

SELL
$3.89 - $7.81 $42,152 - $84,629
-10,836 Reduced 90.53%
1,133 $6,000
Q1 2022

May 11, 2022

BUY
$6.47 - $16.99 $42,152 - $110,689
6,515 Added 119.45%
11,969 $78,000
Q4 2021

Feb 10, 2022

BUY
$16.12 - $31.02 $36,866 - $70,942
2,287 Added 72.21%
5,454 $88,000
Q3 2021

Nov 12, 2021

BUY
$17.0 - $32.84 $53,839 - $104,004
3,167 New
3,167 $84,000

Others Institutions Holding IMRX

About Immuneering Corp


  • Ticker IMRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 26,392,300
  • Market Cap $55.4M
  • Description
  • Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to tr...
More about IMRX
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.